このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Processa Pharmaceuticals 過去の業績

過去基準チェック /06

Processa Pharmaceuticalsの収益は年平均-26.4%で減少しているが、Pharmaceuticals業界はdecliningで0.4%年平均の収益となった。

主要情報

-26.4%

収益成長率

-1.9%

EPS成長率

Pharmaceuticals 業界の成長	6.0%
収益成長率	n/a
株主資本利益率	-110.6%
ネット・マージン	n/a
前回の決算情報	31 Mar 2024

Recent updates

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Dec 12

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Oct 20

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

Aug 12

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Jul 07

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Jan 20

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Aug 26

Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow

Jun 15

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Mar 15

Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look

Jan 29

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Jan 20

収支内訳

Processa Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:PCSA 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
31 Mar 24	-10	4	6
31 Dec 23	-11	6	6
30 Sep 23	-22	7	8
30 Jun 23	-26	9	10
31 Mar 23	-28	10	11
31 Dec 22	-27	9	11
30 Sep 22	-18	7	10
30 Jun 22	-15	6	9
31 Mar 22	-13	5	7
31 Dec 21	-11	5	7
30 Sep 21	-23	5	7
30 Jun 21	-23	4	5
31 Mar 21	-20	3	4
31 Dec 20	-19	3	3
30 Sep 20	-6	2	2
30 Jun 20	-4	2	2
31 Mar 20	-4	2	2
31 Dec 19	-4	2	2
30 Sep 19	-3	1	2
30 Jun 19	-3	1	2
31 Mar 19	-3	1	3
31 Dec 18	-4	1	3
30 Sep 18	-4	1	3
30 Jun 18	-4	1	3
31 Mar 18	-3	1	2
31 Dec 17	-2	1	1
31 Dec 16	-2	0	2

質の高い収益: PCSAは現在利益が出ていません。

利益率の向上: PCSAは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: PCSAは利益が出ておらず、過去 5 年間で損失は年間26.4%の割合で増加しています。

成長の加速: PCSAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: PCSAは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 19.9% ) と比較することは困難です。

株主資本利益率

高いROE: PCSAは現在利益が出ていないため、自己資本利益率 ( -110.61% ) はマイナスです。

Processa Pharmaceuticals 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.

Processa Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2024

Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research

Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial

New major risk - Shareholder dilution

Co-Founder recently bought US$51k worth of stock

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Processa Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.99989 million.

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $14.35 million.

Processa Pharmaceuticals, Inc. Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety over Capecitabine

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Processa Pharmaceuticals, Inc. Provides Data Update Supporting A Potential Personalized Treatment Approach for Improved Cancer Care

Processa Pharmaceuticals, Inc. Appoints George Ng as Chief Executive Officer

New major risk - Share price stability

New major risk - Market cap size

Processa Pharmaceuticals, Inc. Announces to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

High number of new and inexperienced directors

Processa Pharmaceuticals, Inc. Announces Positive Gastric Emptying Results from its Pcs12852 Phase 2A Trial in Patients

Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Processa Pharmaceuticals, Inc. Provides Update on Enrollment Across All Clinical Programs

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

High number of new and inexperienced directors

Processa Pharmaceuticals, Inc. Announces Board Changes

Processa Pharmaceuticals, Inc. Elects Khoso Baluch as Director

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Processa Pharmaceuticals, Inc., Annual General Meeting, Jul 11, 2022

Price target decreased to US$15.00

Processa Pharmaceuticals, Inc. Doses First Patient in Amended Phase 1B Protocol for Pcs6422 Combined with Capecitabine

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer

Co-Founder recently bought US$77k worth of stock

Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow

Processa Pharmaceuticals, Inc. Announces First Patient Dosed in Its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Processa Pharmaceuticals, Inc. Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Processa Pharmaceuticals, Inc. announced that it has received $10.238773 million in funding

New 90-day high: US$10.89

Processa Pharmaceuticals, Inc. announced that it expects to receive $10.238773 million in funding

Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Processa Pharmaceuticals, Inc. Announces Executive Changes

Processa Pharmaceuticals, Inc. Appoints R. Michael Floyd as Chief Operating Officer

Co-Founder recently bought US$125k worth of stock

Processa Pharmaceuticals, Inc. has completed an IPO in the amount of $19.2 million.

New 90-day low: US$3.95

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06